Making injections safer, every time.
Aspiel is a healthcare startup focused on improving injection safety. It has developed a first-in-the-world device that separates aspiration from injection, making this safety check easier and more consistent for users and helping reduce accidental injections into blood vessels. The technology is backed by patents, clinical validation, and regulatory approvals, including CDSCO marketing clearance in India. Clinical research evaluating this innovation has been accepted for publication in BMJ Innovations.
Non-Dilutive Grants: BIRAC BIG – ₹50L; Industries Commissionerate, Government of Gujarat – ₹20L; NIDHI-PRAYAS – ₹5L; SSIP, Government of Gujarat – ₹2.5L
One granted patent and two pending patents (PCT route). Registered trademark. Design patent and registrations across India, EU, UK, Australia, Canada, and Australia (pending in USA). Favorable international patentability (IPRP) report from WIPO.
The company operated in stealth mode during product development, regulatory approvals, and clinical validation. The clinical research evaluating this innovation has been accepted for publication in BMJ Innovations.
Aspiel is led by a multidisciplinary team of clinician-innovators, alumni of B J Medical College, Ahmedabad, supported by a former IIT Gandhinagar tech specialist. The team leverages clinical insight and expertise in medical device development, regulatory affairs, and clinical research, with collaboration and incubation support from AIC-LMCP, Ahmedabad.
Co-Founder
C-Founder
Director of Operations
Prototype Development
